tiprankstipranks
Infant Bacterial Therapeutics AB (DE:9IB)
BERLIN:9IB
Germany Market

Infant Bacterial Therapeutics AB (9IB) Income Statement

Compare
4 Followers

Infant Bacterial Therapeutics AB Income Statement

Last quarter (Q4 2024), Infant Bacterial Therapeutics AB's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q4, Infant Bacterial Therapeutics AB's net income was kr-33.77M. See Infant Bacterial Therapeutics AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
kr 77.00Kkr 12.00Kkr 0.00kr 0.00kr 0.00
Gross Profit
kr 77.00Kkr 12.00Kkr 0.00kr 0.00kr -816.00K
Operating Expenses
kr 134.69Mkr 65.81Mkr 44.58Mkr 71.92Mkr 47.20M
Depreciation and Amortization
kr 134.62Mkr 816.00Kkr 816.00Kkr 816.00Kkr 816.00K
EBITDA
kr 11.55Mkr -65.45Mkr -44.99Mkr -72.01Mkr -45.50M
Operating Income
kr -134.62Mkr -65.81Mkr -44.58Mkr -71.92Mkr -47.20M
Other Income/Expenses
kr 11.55Mkr 357.00Kkr -413.00Kkr -89.00Kkr 880.00K
Pretax Income
kr -123.07Mkr -65.45Mkr -44.99Mkr -72.01Mkr -46.32M
Net Income
kr -123.07Mkr -65.09Mkr -45.40Mkr -72.31Mkr -47.05M
Per Share Metrics
Basic EPS
kr -9.95kr -5.80kr -4.04kr -6.44kr -4.19
Diluted EPS
kr -9.95kr -5.80kr -4.04kr -6.44kr -4.19
Weighted Average Shares Outstanding
12.36M 11.23M 11.23M 11.23M 11.23M
Weighted Average Shares Outstanding (Diluted)
12.36M 11.23M 11.23M 11.23M 11.23M
Currency in SEK

Infant Bacterial Therapeutics AB Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis